With data indicating that it is the most common pediatric rheumatologic disease, juvenile idiopathic arthritis (JIA) can impact quality of life and cause disability starting in childhood. Despite hope that the growing use of...
Read More
THURSDAY, May 21, 2020 (HealthDay News) — Clinically important increases in melanoma risk in...
Read More THURSDAY, May 21, 2020 (HealthDay News) — In an updated American College of Rheumatology...
Read More
1990 to 2017 saw jump of 9.3 and 8.2 percent in age-standardized point prevalence, annual incidence
Read More At 21 days, survival was 90 percent in anakinra group versus 56 percent in standard treatment group
Read More
Prior research indicates that fractures, as the most clinically relevant endpoint of osteoporosis,...
Read More Recommendations address the uncertainties faced by clinicians in the detection, diagnosis of sarcoidosis
Read MoreTofacitinib leads to lasting improvements in dermatologic symptoms in OPAL Broaden and OPAL Beyond trials Oral tofacitinib is a viable treatment option for patients with active psoriatic arthritis (PsA) who have had an...
Read More Among psoriasis patients, those on systemic treatment had lower risk for Alzheimer disease
Read More